Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/henlius-releases-2023-esg-report-pursuing-sustainable-development-with-patient-centricity-302119490.html
https://www.prnewswire.com/news-releases/henlius-forecasts-profit-in-2023-achieving-first-full-year-of-profitability-and-ushering-in-a-new-phase-of-high-quality-development-302078510.html
https://www.prnewswire.com/news-releases/the-nda-for-new-indication-of-henlius-anti-pd-1-mab-serplulimab-in-combination-with-chemotherapy-for-the-first-line-treatment-of-non-squamous-nsclc-accepted-by-the-nmpa-302012575.html
https://www.prnewswire.com/news-releases/henlius-reported-financial-results-for-the-first-three-quarters-of-2023-total-revenue-exceeded-rmb3-9-billion-profitability-further-improved-301989017.html
https://www.prnewswire.com/news-releases/henlius-deepens-collaboration-with-intas-to-bring-henlius-novel-anti-pd-1-mab-serplulimab-to-europe-and-india-301970103.html
https://www.prnewswire.com/news-releases/henlius-novel-anti-pd-1-mab-hansizhuang-serplulimab-approved-for-the-treatment-of-escc-301936785.html
https://www.prnewswire.com/news-releases/henlius-expands-collaboration-with-kgbio-to-develop-commercialize-and-supply-henlius-novel-anti-pd-1-mab-hansizhuang-in-mena-301924516.html
https://www.prnewswire.com/news-releases/henlius-2023-h1-results-achieved-record-profits-and-rmb2-5-billion-revenues-opening-a-new-chapter-of-high-quality-growth-301910042.html
https://www.prnewswire.com/news-releases/henlius-achieved-steep-revenue-growth-in-q1-2023-core-products-sales-surged-301798411.html
https://www.prnewswire.com/news-releases/henlius-2022-annual-results-significant-achievements-in-commercialisation-surged-to-rmb3-2-billion-in-revenues-301787220.html